Latest Biochemistry (medical) research

Top 6 this week

Week of 1 November 2026

1. 1

   Short and long-term outcomes after gestational diabetes diagnosis using different glycemic criteria: a systematic review and meta-analysis

   The Journal of clinical endocrinology and metabolism · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 30 October 2026

   Across studies involving 81,528 women, lower glucose thresholds doubled gestational diabetes diagnoses and medication use, but had little effect on most short-term outcomes. They were linked to 18 more cases of neonatal hypoglycemia per 1,000 births; possible longer-term benefits come from just one trial, so whether lower thresholds improve health overall remains uncertain.

2. 2

   Therapeutic Interventions in Niemann-Pick Disease Type C: A Systematic Review of Clinical Outcomes and Safety

   Biomedicines · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 21 October 2026

   Inherited lysosomal lipid-trafficking disease and cholesterol biomarker target engagement

3. 3

   Effects of selenium supplementation on glycemic indices and oxidative-stress biomarkers in adults: a systematic review, meta-analysis, and dose-response analysis of randomized controlled trials

   Nutrition journal · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 1 August 2026

   A review of randomized trials found selenium improved insulin-sensitivity measures and some antioxidant, inflammatory, and lipid markers, but did not clearly lower fasting glucose or glycated hemoglobin overall. Effects varied by dose, duration, and participants' selenium status, so benefits may not apply in selenium-replete populations; long-term safety and the best dose remain unclear.

4. 4

   A multicohort proteomics-based machine learning score (MASHPredict) for noninvasive diagnosis and long-term prognostication of metabolic dysfunction-associated steatohepatitis

   Frontiers in immunology · Q1 journal · RCT · Evidence level 5 (Expert Opinion) · 15 October 2026

   Validated plasma proteomic diagnostic score for metabolic liver disease

5. 5

   Meal-induced changes in cardiometabolic peptides in the context of acute cardiovascular diseases and glucose metabolism

   Cardiovascular diabetology · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 26 October 2026

   Human meal challenge links metabolic state to peptide biomarkers

6. 6

   Prognostic value of multiple biomarkers for kidney function decline in type 2 diabetes with relatively preserved kidney function: a systematic review and exploratory meta-analysis

   Frontiers in endocrinology · Q1 journal · SR of cohorts · Evidence level 2 (Moderate) · 12 October 2026

   Reviews circulating and urinary biomarkers in diabetic kidney disease

Paper of the day, last two weeks

• Clinical Outcomes after Deprescribing Thyroid Hormone Therapy: An Updated Systematic Review and Meta-Analysis

  Thyroid : official journal of the American Thyroid Association · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 2 November 2026

  Across 23 studies, 41% of patients initially treated for subclinical hypothyroidism remained euthyroid after supervised thyroid hormone withdrawal, compared with 11% of those with overt hypothyroidism. Overall, 60% restarted therapy, while symptoms generally did not change and adverse events were uncommon. Most evidence was observational and highly variable, so deprescribing calls for close monitoring and clear restart criteria.

• Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome

  Frontiers in microbiology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 15 October 2026

  Across 12 clinical trials involving 696 people with metabolic syndrome, probiotics or synbiotics were linked to modest reductions in weight, waist size and blood fats, including triglycerides by about 20 mg/dL. Fasting blood sugar did not significantly improve in patients, despite stronger metabolic effects in animal studies; longer, higher-quality trials are needed to confirm clinical benefits.

• Clinical performance of sFlt-1/PlGF ratio triage in suspected pre-eclampsia: A prospective, observational multicenter diagnostic-triage study in South Africa (TsHEPPO study)

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 28 October 2026

  In 555 South African women assessed for suspected pre-eclampsia, a ratio of 33 or higher had a 91% positive predictive value, meaning about 9 in 10 positive results occurred in women diagnosed with the condition. Both tested thresholds were sensitive for pre-eclampsia within 7 days, but their ability to rule it out weakened by 28 days, supporting use alongside clinical assessment and reassessment when needed.

• Assessment of Non-Invasive Tests for MASLD, MASH and At-Risk MASH in a Multicentre Prospective Real-World Study

  Diabetes, obesity & metabolism · Q1 journal · Cohort · Evidence level 3 (Low) · 27 October 2026

  Prospective validation of noninvasive MASLD biomarkers against biopsy

• Assessment of Non-Invasive Tests for MASLD, MASH and At-Risk MASH in a Multicentre Prospective Real-World Study

  Diabetes, obesity & metabolism · Q1 journal · Cohort · Evidence level 3 (Low) · 27 October 2026

  Prospective validation of noninvasive MASLD biomarkers against biopsy

• Palopegteriparatide in Adults With Hypoparathyroidism: 3.5-Year Results From the Phase 3 PaTHway Trial

  The Journal of clinical endocrinology and metabolism · Q1 journal · RCT · Evidence level 1 (High) · 27 October 2026

  PTH replacement with calcium, renal, and bone biochemical monitoring

• A phase 2b/3 trial of saroglitazar in primary biliary cholangitis

  Hepatology (Baltimore, Md.) · Q1 journal · RCT · Evidence level 1 (High) · 26 October 2026

  In a 52-week randomized trial of patients who could not adequately use ursodeoxycholic acid, 56.7% receiving saroglitazar met the biochemical response target, compared with 9.8% on placebo. Alkaline phosphatase normalized in 8.2% versus none, while an itch benefit seen at 24 weeks was not sustained at one year; longer-term outcomes remain unknown.

• A Two-Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p-Tau217 Gray Zone

  Annals of clinical and translational neurology · Q1 journal · Unclassified · Evidence level 5 (Expert Opinion) · 19 October 2026

  Plasma biomarker performance and reflex testing for Alzheimer’s disease

• Effects of liraglutide on blood pressure and renal function in patients with type 2 diabetic nephropathy: a meta-analysis of randomized controlled trials

  Frontiers in medicine · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 9 October 2026

  Across 23 randomized trials involving 1,723 people with type 2 diabetic nephropathy, liraglutide lowered systolic blood pressure by an average of 5 mm Hg, while diastolic pressure did not change significantly. Several kidney markers also improved, but whether these changes translate into better long-term kidney outcomes remains unknown, and the authors call for higher-quality studies.

• Comparative effects of different exercise modalities and doses on lipid metabolism in patients with type 2 diabetes mellitus: a systematic review with Bayesian dose-response network meta-analysis

  Frontiers in endocrinology · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 7 October 2026

  Systematic synthesis of exercise effects on lipid metabolism